Answers are grounded in this paper and cite their sources.
BACKGROUND: Cryptococcal antigen (CrAg) screening and pre-emptive treatment of antigenemia can reduce mortality among people living with HIV. SETTING: We evaluated the effectiveness of a national CrAg screening program in South Africa. METHODS: We enrolled a retrospective cohort of adults aged ≥18 years with a CD4 count <100 cells/µL and new antigenemia diagnosis at 442 facilities in a stratified-random sample of 27 subdistricts, 2017-2019. We determined a composite outcome of incident cryptococcal meningitis or death through 6 months. RESULTS: Overall, 99% (85,791/86,274) of eligible patients had CrAg testing in the study subdistricts; 5124 (6.0%) tested CrAg positive. Among 1651 with imaged medical records and without concurrent meningitis, 76% (1261/1651) were outpatients. CrAg results were documented in records for 75% (1245/1651). Only 39% (649/1651) had a meningitis symptom review documented at a median of 14 days (IQR, 5-44) from their CrAg blood draw. Fluconazole was dispensed for 50% (827/1651) but only 32% (523/1651) had an adequate daily dose of ≥800 mg dispensed. The proportion with meningitis or death within 6 months was 23% (382/1651; 95% CI: 19% to 27%). Hospitalized patients had a 2.29 higher adjusted odds of meningitis/death within 6 months vs. outpatients (95% CI: 1.72 to 3.04; P < 0.001). CONCLUSIONS: Nationwide reflex laboratory CrAg screening was successfully implemented. However, challenges existed for health care providers to act on positive CrAg results to exclude meningitis and dispense pre-emptive antifungal therapy. Our findings emphasize the critical need for improved linkage from reflex CrAg screening to clinical care, in both ambulatory and in-patient settings, to maintain the effectiveness of this intervention.
No takes yet. Share an insight, caveat, or question.
Govender et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: